WXIBF (WuXi Biologics (Cayman)) Accounts Payable: $155 Mil (As of Dec. 2025)


WXIBF WuXi Biologics (Cayman) Inc WXIBF
97 GF Score
Price $4.60
GF Value $5.14
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Accounts Payable?

WuXi Biologics (Cayman) WXIBF 97 Accounts Payable is $155 Mil as of Dec. 2025. GuruFocus rates WXIBF with a GF Score™ of 97/100 and a GF Value™ of $5.14 (Modestly Undervalued). The stock has 3 warning signs investors should review.

WuXi Biologics (Cayman)'s Accounts Payable for the quarter that ended in Dec. 2025 was $155 Mil.

WuXi Biologics (Cayman)'s quarterly Accounts Payable increased from Dec. 2024 ($103 Mil) to Jun. 2025 ($135 Mil) and increased from Jun. 2025 ($135 Mil) to Dec. 2025 ($155 Mil).

WuXi Biologics (Cayman)'s annual Accounts Payable declined from Dec. 2023 ($117 Mil) to Dec. 2024 ($103 Mil) but then increased from Dec. 2024 ($103 Mil) to Dec. 2025 ($155 Mil).

WuXi Biologics (Cayman) Accounts Payable Related Terms

WuXi Biologics (Cayman) Accounts Payable Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Accounts Payable Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 96.99 113.95 116.70 102.62 154.98

WuXi Biologics (Cayman) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 116.70 120.55 102.62 135.01 154.98
WXIBF
97GF Score
WuXi Biologics (Cayman) Inc WXIBF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi Biologics (Cayman) Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $155 Mil mean?
WuXi Biologics (Cayman) (WXIBF) has a Accounts Payable of $155 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s Accounts Payable too high?
WuXi Biologics (Cayman)'s current Accounts Payable is $155 Mil. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Accounts Payable compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Accounts Payable of $155 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Accounts Payable is $155 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.14, compared to a current price of $4.60 — trading 10.5% below its estimated fair value. The current Accounts Payable is $155 Mil. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Accounts Payable is $155 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of $4.60 is trading 10.5% below its estimated GF Value™ of $5.14. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.

Key valuation signals for WXIBF:

  • Accounts Payable: $155 Mil
  • GF Value™: $5.14 vs. price of $4.60 (10.5% below fair value)
  • GF Score™: 97/100 with 3 warning signs

No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score

Get the complete analysis for WXIBF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.60
Price
$5.14
GF Value